ICIs Boost pCR in Early Triple-Negative Breast Cancer
Immune drugs combined with chemotherapy improve results for triple-negative breast cancer
Adding immune checkpoint inhibitors to chemotherapy improves pathological complete response in early triple-negative breast cancer, with PD-…
Adding immune checkpoint inhibitors to chemotherapy significantly increases the chance of clearing cancer cells in triple-negative breast ca…
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…
Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
Targeted therapy plus chemotherapy improves response in triple-negative breast cancer
This systematic review and meta-analysis of 523 patients found that adding targeted therapy to chemotherapy for advanced triple-negative bre…
Adding targeted therapy to chemotherapy may improve how tumors respond in patients with advanced triple-negative breast cancer.
Adjuvant CDK4/6 inhibitors improve invasive Disease-Free Survival regardless of patient menopausal status
CDK4/6 inhibitors show consistent results for both pre and postmenopausal women
This meta-analysis of 17,748 patients with HR+ and HER2-negative early breast cancer found that adjuvant CDK4/6 inhibitors improved invasive…
New data suggests that a specific type of breast cancer treatment works effectively regardless of whether a patient has reached menopause.
Neoadjuvant immune checkpoint inhibitors plus chemotherapy increase pathological complete response in early-stage triple-negative breast cancer
Immune checkpoint inhibitors improve response in triple-negative breast cancer
This meta-analysis of 3,377 patients found that neoadjuvant immune checkpoint inhibitors combined with chemotherapy significantly increased …
Adding immune checkpoint inhibitors to chemotherapy helps more patients with early-stage triple-negative breast cancer achieve a complete re…
Chemokine networks regulate triple-negative breast cancer tumor microenvironment but clinical translation remains limited
Chemokine Targets Show Promise in Lab but Face Clinical Hurdles
This systematic review examines the role of chemokine networks and targeted interventions in the triple-negative breast cancer immune microe…
New research highlights the role of chemokine networks in breast cancer, showing strong results in labs despite challenges in current clinic…
Datopotamab deruxtecan improves progression-free survival to 10.8 months versus 5.6 months in TNBC
Trial shows datopotamab deruxtecan improves survival in triple-negative breast cancer
This Phase III randomized controlled trial of 644 patients with untreated, locally recurrent inoperable or metastatic triple-negative breast…
A new trial shows that datopotamab deruxtecan may extend progression-free and overall survival for patients with advanced triple-negative br…
Adenomatoid tumor should be considered in the differential diagnosis for testicular lesions in patients with cryptorchidism
Testicular Adenomatoid Tumor Linked to History of Cryptorchidism
This case report and literature review describes a 58-year-old man with cryptorchidism, male breast cancer, and thymic B2 thymoma who presen…
A new case report highlights a link between undescended testes and certain benign testicular tumors, helping doctors better identify similar…
Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
Immunotherapy plus chemo improves survival in triple-negative breast cancer
This umbrella meta-analysis of 39,147 patients found that combining immune checkpoint inhibitors with chemotherapy significantly improves ov…
Adding immunotherapy to chemo helps some patients with advanced triple-negative breast cancer live longer, but side effects are more common.
Multimodal fusion and radiogenomic frameworks show promise for capturing heterogeneity in triple-negative breast cancer
Artificial Intelligence Shows Promise in Triple-Negative Breast Cancer Care
This narrative synthesis reviews the application of artificial intelligence across radiology, digital pathology, and multi-omics for triple-…
New research shows how artificial intelligence can help identify cancer subtypes and predict treatment responses for patients with triple-ne…
Small intestinal metastasis from triple-negative breast cancer can mimic lymphoma on imaging
Case report: Breast cancer spread to small intestine mimics lymphoma
This case report with literature review describes a patient with triple-negative breast cancer who developed small intestinal metastasis pre…
A breast cancer survivor's anemia was caused by a rare small intestine metastasis that looked like lymphoma on scans.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Research across Cancer
Related studies from across the Cancer family.
Rezvilutamide plus ADT with efavirenz-based ART yields PSA decline in one HIV-positive mHSPC patient
Rezvilutamide Shows Promise for Prostate Cancer in HIV Patients
This is a single-patient case report describing rezvilutamide plus androgen deprivation therapy in an HIV-positive patient with high-volume …
A single patient with both HIV and advanced prostate cancer showed significant improvement after starting a specific combination of treatmen…
Meridian Sinew Tuina significantly reduces upper limb circumference and pain in breast cancer-related lymphedema
Meridian Sinew Tuina May Help Manage Breast Cancer Lymphedema
This meta-analysis evaluated the impact of Meridian Sinew Tuina on patients with breast cancer-related lymphedema. The analysis found signif…
A specialized deep tissue massage technique called Meridian Sinew Tuina shows promise in reducing swelling and pain for those with breast ca…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
Lead-in therapy may reduce severe low white blood cell counts
This post hoc analysis of a phase 3 trial and real-world validation study evaluated lead-in androgen-deprivation therapy (ADT) for patients …
A new look at clinical data suggests that a lead-in hormone treatment can help prevent serious low white blood cell counts in prostate cance…
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Lymphovenous anastomosis improves quality of life in breast cancer-related lymphedema
Lymphedema surgery improves quality of life in breast cancer survivors
This meta-analysis of observational studies found that therapeutic lymphovenous anastomosis (LVA) significantly improves quality of life in …
A new analysis finds that lymphovenous anastomosis significantly boosts quality of life for breast cancer survivors with lymphedema, especia…
Weight reduction ranked highest for limb volume, while VR-based training ranked highest for pain in breast cancer-related lymphedema
Weight loss and virtual reality rank highest for breast cancer swelling and pain relief
This network meta-analysis of 754 patients evaluated non-pharmacological therapies for breast cancer-related lymphedema. Weight reduction ra…
Weight loss and virtual reality training ranked best for reducing arm swelling and pain in breast cancer patients, though other therapies al…
Healthcare professionals need updated guidance on managing breast cancer-related lymphedema effectively today
Review updates care for breast cancer-related lymphedema
This narrative review aims to apprise healthcare professionals with the latest understanding of optimal care and counseling patients regardi…
A new review summarizes the latest understanding of breast cancer-related lymphedema to help healthcare professionals counsel patients.
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
Questions about Hormone Receptor-Positive Breast Cancer
Is trastuzumab deruxtecan better than chemotherapy for HR-positive breast cancer?
Yes, trastuzumab deruxtecan improves progression-free survival compared to chemotherapy in HR-positive, HER2-low breast cancer, but overall survival data are not yet mature.
Full answer →Does datopotamab deruxtecan improve survival for Hormone Receptor-Positive Breast Cancer?
Datopotamab deruxtecan did not improve overall survival compared to chemotherapy in metastatic HR-positive breast cancer, despite improving progression-free survival.
Full answer →All Hormone Receptor-Positive Breast Cancer Articles
- ICIs Boost pCR in Early Triple-Negative Breast Cancer
- Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
- Targeted therapy plus chemotherapy improves objective response and disease control rates in advanced TNBC
- Adjuvant CDK4/6 inhibitors improve invasive Disease-Free Survival regardless of patient menopausal status
- Neoadjuvant immune checkpoint inhibitors plus chemotherapy increase pathological complete response in early-stage triple-negative breast cancer
- Chemokine networks regulate triple-negative breast cancer tumor microenvironment but clinical translation remains limited
- Datopotamab deruxtecan improves progression-free survival to 10.8 months versus 5.6 months in TNBC
- Adenomatoid tumor should be considered in the differential diagnosis for testicular lesions in patients with cryptorchidism
- Immune checkpoint inhibitors plus chemotherapy improve overall survival in advanced triple-negative breast cancer
- Multimodal fusion and radiogenomic frameworks show promise for capturing heterogeneity in triple-negative breast cancer
- Small intestinal metastasis from triple-negative breast cancer can mimic lymphoma on imaging
- Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
- Chemo-immunotherapy yields 12-month disease-free status in rare triple-negative neuroendocrine breast cancer
- Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
- Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
- Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
- Gut microbiome factors and dietary modulation may optimize triple-negative breast cancer management
- Docetaxel chemotherapy is highly suspect for causing acute myocardial infarction in a low-risk triple-negative breast cancer patient
- Fulvestrant maintenance improves PFS versus capecitabine in HR+ HER2- metastatic breast cancer
- Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
- Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
- Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
- Radiofrequency ablation followed by radiation therapy shows noninferior 5-year recurrence-free survival compared to partial mastectomy in early stage breast cancer
- CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
- Capivasertib-paclitaxel fails to improve overall survival in metastatic TNBC
- Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
- AI-mediated ultrasonic radiomics shows potential for triple-negative breast cancer diagnosis and prognosis
- Review of immunotherapy innovations for triple-negative breast cancer survival
- Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
- Meta-analysis finds oral SERDs improve PFS over standard ET in HR+ HER2- ABC
- Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
- Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms
- Adherence to 2021 ABS imaging recommendations in 148 male breast referrals at a UK hospital
- Sequential paclitaxel-palbociclib showed no difference in ORR versus reverse sequence in ER+/HER2- breast cancer
- Meta-analysis finds immunotherapy plus chemotherapy improves outcomes in triple-negative breast cancer
- Pyroptosis-related gene signature predicts prognosis in triple-negative breast cancer patients
- Neoadjuvant chemotherapy plus sintilimab improved response rates versus chemotherapy alone in 61 patients with triple-negative breast cancer
- Network meta-analysis of adjuvant chemotherapy regimens for early-stage breast cancer identifies optimal dosing sequences and safety profiles
- Atezolizumab plus chemotherapy improved progression-free survival and patient-reported quality of life in metastatic triple-negative breast cancer
- Phase Ib trial: Mam-A DNA vaccine plus endocrine therapy induces T cells in ER+ breast cancer
- PSMA PET/CT shows uptake in half of metastatic triple-negative breast cancer patients
- Population study links PALB2 variants to increased cancer risk and mortality in two large cohorts
- DIBH reduces radiation dose to heart and lungs in left-sided breast cancer VMAT
- Single-fraction stereotactic partial breast irradiation shows promising early control in early-stage breast cancer
- Adjusted Breast Cancer Index model identifies minimal-risk groups in premenopausal HR+ node-negative breast cancer